Cannabis Report
Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

Agreed. Investor NDAs covered (a) the existence and

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
thermoo Member Profile
 
Followed By 4
Posts 33
Boards Moderated 0
Alias Born 10/27/16
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/28/2018 5:23:29 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/28/2018 4:12:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/18/2018 5:16:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/1/2018 4:34:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/31/2018 5:01:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/31/2018 7:03:23 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/21/2018 4:44:29 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/16/2018 5:06:32 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/16/2018 4:42:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2018 5:26:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/2/2018 3:52:43 PM
Traders News Source Issues Research Reports on ANDI, FUSZ, RNVA and NWBO InvestorsHub NewsWire - 4/19/2018 8:00:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 4/17/2018 5:11:43 PM
Revised Proxy Soliciting Materials (definitive) (defr14a) Edgar (US Regulatory) - 4/12/2018 5:26:20 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/9/2018 4:15:48 PM
Proxy Soliciting Materials (revised) (prer14a) Edgar (US Regulatory) - 4/4/2018 5:19:57 PM
Notification That Annual Report Will Be Submitted Late (nt 10-k) Edgar (US Regulatory) - 4/3/2018 6:07:43 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 3/26/2018 5:18:11 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 3/26/2018 5:12:56 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/22/2018 4:41:41 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/20/2018 5:11:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/15/2018 5:21:44 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/7/2018 4:06:26 PM
StereoVision (SVSN) $420 million in Sales from $1,000 Acre Hemp Farm Lease InvestorsHub NewsWire - 3/6/2018 6:47:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/2/2018 5:27:04 PM
thermoo   Thursday, 12/07/17 06:15:23 PM
Re: VuBru post# 148261
Post # of 182895 
Agreed. Investor NDAs covered (a) the existence and terms of the transaction prior to those being released in an 8k (this would include voting arrangements, etc), and (b) a separate NDA covering certain fundamental information about the trial / company.

All investors would have to sign "a". This NDA would prohibit trading until the 8k is released. NDA "b", while optional, would give long term investors comfort that the technology is compelling. The can't sell until the fundamental data is publicly available but why would they? If there is a significant therapeutic benefit, the stock is not going to stop at $0.50


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist